佟仲生

来自医学百科
佟仲生

姓名:佟仲生

性别:男

籍贯:中国

职称主任医师、硕士生导师

就职医院天津市肿瘤医院

所在科室: 乳腺肿瘤内科

出诊时间:周一上午(具体以当天公示为准)[1]

擅长乳腺癌的新辅助、辅助及晚期乳腺癌的化学治疗。

人物简介

佟仲生,男,医学硕士。主任医师,硕士生导师。现就职于天津市肿瘤医院乳腺肿瘤内科,任天津市肿瘤医院乳腺肿瘤内科主任。

专业特长

从事肿瘤专业化疗临床与基础研究工作多年,具有丰富肿瘤学专业造诣及临床实践经验,作为乳腺肿瘤内科治疗的学科带头人,尤精于乳腺癌综合治疗。对乳腺癌的新辅助、辅助及晚期乳腺癌的化学治疗有较深造诣。

教育执业经历

1986年毕业于天津医科大学医学系获学士学位,天津医科大学肿瘤学硕士。

2004-2005年作为访问学者在美国密西根大学基础与临床工作。

科研与论著

主持多项抗癌新药的Ⅰ、Ⅱ、Ⅲ期临床研究,参与国际多中心临床研究工作40余项,目前承担多项国家、市级重大专项等课题研究,率先开展局部晚期乳腺癌光动力治疗的基础与临床研究,开辟了光动力转化医学研究新领域,并获2014年度天津科技进步三等奖。多次受邀参加国内外学术会议大会发言。

国内外发表论文80余篇,主编论著1部。参与完成论著7部。

学术任职

中国抗癌协会靶向治疗专业委员会常委、天津市抗癌协会临床化疗专业委员会主任委员、天津市医药学专家协会肿瘤专业委员会主任委员、中国乳腺癌专业委员会委员、天津医学会肿瘤学分会委员。

《中国肿瘤临床》杂志编委、《天津医药》编委、《中国综合临床》编委。

发表论文

Ge J, Yu Y, Xin F, Yang ZJ, Zhao HM, Wang X, Tong ZS, Cao XC. Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis in patients with breast cancer.Cancer Sci. 2017 Feb 3.[Epub ahead of print]

Wang S, Li W, Wang F, Niu Y, Hao C, Wang X, He L, Tong Z. 36 cases adenoid cystic carcinoma of the breast in China: Comparison with matched grade one invasive ductal carcinoma-not otherwise specified. Pathol Res Pract. 2017 Apr;213(4):310-315.

Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017 Mar;18(3):371-383.

Zhang L, Wu Y, Liu F, Fu L, Tong Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. Oncotarget. 2016 Aug 9;7(32):52450-52459.

Shi YH, Dai DF, Li J, Dong YW, Jiang Y, Li HG, Gao Y, Chong CK, Li HY, Chu XQ, Yang C, Zhang Q, Tong ZS, Bai CG, Chen Y. Sulforaphane Analogues with Heterocyclic Moieties: Syntheses and Inhibitory Activities against Cancer Cell Lines. Molecules. 2016 Apr 21;21(4):514.

Zhang P, Tong Z, Tian F, Wang Y, Yang J, Li W, Di L, Liu W, Tang L, Qiu R, Xu B. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. J Hematol Oncol. 2016 Aug 11;9(1):68.

Zhang Q, Shao Z, Shen K, Li L, Feng J, Tong Z, Gu K, Wang X, Xu B, Sun G, Chen H, Rukazenkov Y, Jiang Z.Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget. 2016 Aug 30;7(35):57301-57309.

Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L, Tong Z, Higuchi K. Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis. Oncotarget. 2016 Jun 14;7(24):35843-35852.

Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L. A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2016 Jan;38(1):23-7.

Zhao W, Wang J, Zhu B, Duan Y, Chen F, Nian W, Sun J, Zhang B, Tong Z, Chen Z. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. Oncol Rep. 2016 Mar;35(3):1483-92.

Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.

Wang C, Ju H, Shen C, Tong Z. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin Exp Med. 2015 Sep 15;8(9):15648-56.

Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.

Lu N, Tong Z, Zhang M, Lu L, Cao H. Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):342-6.

Yuan P, Di LJ, Liu W, Wan DG, Dai H, Tong ZS, Du F, Xu BH. Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patients. Int J Clin Exp Med. 2015 Feb 15;8(2):3072-9.

Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J, Shen K, Sun T, Teng Y, Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P, Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S. National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Ann Transl Med. 2015 Oct;3(17):242.

Jia Y, Zhang C, Zhou L, Xu H, Shi Y, Tong Z. Micheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathione. Onco Targets Ther. 2015 Aug 28;8:2319-27.

Dong G, Jia Y, Wang X, Li S, Wang C, Shi Y, Tong Z. The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer. Int J Clin Exp Med. 2015 May 15;8(5):8283-7.

Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):436-46.

Wang F, Jia Y, Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015 Feb;45(2):146-52.

F Wang, Y Jia, Z Tong*. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor[J]. Jpn J Clin Oncol, 2015,45 (2): 146-152.

C Lu, W Wang, Y Jia, X Liu, Z Tong*, B Li*. Inhibition of AMPK/autophagy potentiates parthenolide-induced apoptosis in human breast cancer cells[J]. J Cell Biochem, 2014,115 (8): 1458-1466.

C Lu, LY Zhou, HJ Xu, XY Chen, Z Tong*, XD Liu, YS Jia, Y Chen. RIP3 overexpression sensitizes human breast cancer cells to parthenolide in vitro via intracellular ROS accumulation[J]. Acta Pharmacol Sin, 2014,35 (7): 929-936.

Lu C, Xu H, Chen X, Tong Z, Liu X, Jia Y. Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: yes or no? Curr Oncol. 2013 Dec;20(6):e585-92

Wei XQ, Li X, Xin XJ, Tong ZS, Zhang S. Clinical features and survival analysis of very young (age<35) breast cancer patients. Asian Pac J Cancer Prev. 2013;14(10):5949-52.

Chen X, Liu X, Zhang L, Li S, Shi Y, Tong Z. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. Jpn J Clin Oncol. 2013 Oct;43(10):954-63.

He LH, Ma Q, Shi YH, Ge J, Zhao HM, Li SF, Tong ZS. CHL1 is involved in human breast tumorigenesis and progression. Biochem Biophys Res Commun. 2013 Aug 23;438(2):433-8.

Z Guan, B Xu, ML DeSilvio, Z Shen, W Arpornwirat, Z Tong, V Lorvidhaya, Z Jiang, J Yang, A Makhson, WL Leung, MW Russo, B Newstat, L Wang, G Chen, C Oliva, H Gomez. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2013,31 (16): 1947-1953.

Q Zhang, Y Lu, Y Ding, J Zhai, Q Ji, W Ma, M Yang, H Fan, J Long, Z Tong, Y Shi, Y Jia, B Han, W Zhang, C Qiu, X Ma, Q Li, Q Shi, H Zhang, D Li, J Zhang, J Lin, LY Li, Y Gao, Y Chen. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells[J]. J Med Chem, 2012,55 (20): 8757-8769.

Z Tong*, P Miao, T Liu, Y Jia, X Liu. Enhanced antitumor effects of BPD-MA-mediated photodynamic therapy combined with adriamycin on breast cancer in mice[J]. Acta Pharmacol Sin, 2012,33 (10): 1319-1324.    L Zhang, C Hao, G Dong, Z Tong*. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China[J]. Breast Care (Basel), 2012,7 (1): 13-17.    C Hao, Y Shi, J Yu, X Wei, S Li, Z Tong*. The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model[J]. Mol Cell Biochem, 2012,367 (1-2): 93-102.

J Li, X Liu, Z Tong*. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer[J]. Jpn J Clin Oncol, 2012,42 (6): 471-476.

C Hao, S Wei, Z Tong*, S Li, Y Shi, X Wang, ZH Zhu. The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro[J]. Tumour Biol, 2012,33 (4): 1159-1167.

T Liu, Z Tong*, L He, L Zhang. Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases[J]. Breast Care (Basel), 2011,6 (6): 446-451.

L Zhang, Z Tong*, S Li, X Ren, B Ren, X Wang, S Cao, C Wang, L He. Quality of Life after Autologous Peripheral Blood Stem Cell Transplantation and High-Dose Chemotherapy in High-Risk Breast Cancer Patients[J]. Breast Care (Basel), 2009,4 (6): 379-386.

Zhang L, Hao C, Dong G, Tong Z. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. Breast Care (Basel). 2012 Feb;7(1):13-17. Epub 2012 Feb 13.

Li J, Liu X, Tong Z. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. Jpn J Clin Oncol. 2012 Jun;42(6):471-6. Epub 2012 Apr 3.

Hao C, Shi Y, Yu J, Wei X, Li S, Tong Z. The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model. Mol Cell Biochem. 2012 Aug;367(1-2):93-102. doi: 10.1007/s11010-012-1323-x. Epub 2012 May 1.

Hao C, Wei S, Tong Z, Li S, Shi Y, Wang X, Zhu ZH. The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro. Tumour Biol. 2012 Aug;33(4):1159-67.

Zhang Q, Lu Y, Ding Y, Zhai J, Ji Q, Ma W, Yang M, Fan H, Long J, Tong Z, Shi Y, Jia Y, Han B, Zhang W, Qiu C, Ma X, Li Q, Shi Q, Zhang H, Li D, Zhang J, Lin J, Li LY, Gao Y, Chen Y.Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem. 2012 Oct 25;55(20):8757-69.

Liu T,Tong Z,He L,Zhang L. Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases. 2011,6:446-451

Overall Survival Benefit Observed with Lapatinib(L) plus Paclitaxel(P) as First-line therapy in patients with HER2-overexpressing metastatic breast cancer .33rd Annual San Antorio Breast Cancer Symposium December 8-12 2010 San Antorio TX USA

国产托烷司琼治疗由顺铂引起恶心呕吐的临床观察佟仲生中国肿瘤临床2005;14;832-834

GP与NP方案治疗对蒽环类及紫杉类耐药转移性乳腺癌的疗效观察佟仲生(通讯作者)实用癌症杂志2009;24卷4期P366-369

重组血管内皮抑素Ⅰ期临床研究佟仲生中华现代内科学杂志2006 VOL3 1150-1155

注射用奈达铂治疗头颈部鳞癌与食管癌及难治非小细胞肺癌Ⅱ期临床试验研究佟仲生(第一作者)肿瘤防治研究杂志2005 VOL 12 No23 1779-1784

芬太尼透皮贴剂在中度癌痛治疗中的临床观察佟仲生(第三作者)中国肿瘤临床2006 VOL 33 577-579

芬太尼透皮贴剂与硫酸吗啡控释片治疗中重度慢性癌痛疗效及不良反应临床观察佟仲生(第二作者)天津医科大学学报2005VOL 11 NO4 586-589

张丽,赵晓辉,佟仲生等. 356例三阴性乳腺癌的临床特征及预后多因素分析中国肿瘤临床2010,37(18):1045-49.

张丽,佟仲生,李淑芬等.自体外周血造血干细胞移植联合大剂量化疗的高危乳腺癌患者生活质量分析中华乳腺病杂志(电子版) 2010,4(3):32-38.

苗培田,佟仲生,张丽等.年龄因素对三阴乳腺癌患者预后的影响;中国肿瘤临床2010,37(22):1304-1308.

苗培田,佟仲生(通讯作者),郝春芳等.三阴乳腺癌120例临床及预后分析;中华医学杂志2010,90(40):2848-2851.

刘婷婷,佟仲生(通讯作者)等,男性与女性乳腺癌预后因素的生存分析《中华医学杂志》2010,90(44):3135-3139.

刘婷婷,佟仲生(通讯作者)等,81例男性乳腺癌临床特征及生存分析《实用肿瘤杂志》2010,25(5):564-568

佟仲生,王晓蕊等,骨胶原代谢指标在乳腺癌骨转移诊断中的应用,2010 30(5)

刘晓东,汪旭,贾勇圣,王蕊,佟仲生.三阴性对小肿块乳腺癌患者预后的影响.中国肿瘤临,2012 Vol. 39 (9): 578-582

于倩;佟仲生;汪旭;史业辉;何丽宏;刘晓东.转移性乳腺癌临床病理特征及预后分析[J]肿瘤.2012,(08)

李军楠、刘晓东、董国雷、佟仲生. 2342例乳腺癌患者临床病理学特征及预后分析,中国肿瘤临床2012年39卷05期

张丽;佟仲生;李淑芬;史业辉;郝春芳.紫杉醇脂质体对卵巢癌细胞生长抑制作用的实验研究[J]实用肿瘤杂志.2012,(01)

史业辉,贾勇圣,佟仲生.人肝癌细胞线粒体DNA变异研究.中华实验外科杂志2012.10

贾勇圣,刘晓东,史业辉,董国雷,佟仲生. KLF4对肝癌细胞HepG2化疗和光动力治疗的调节作用.中国肿瘤生物治疗杂志,2012,(4) :397~401

邱梅清、佟仲生、贾勇圣、董国雷、郝春芳.老年性乳腺癌预后多因素分析,实用肿瘤杂志,2012.

邱梅清,佟仲生,郝春芳,贾勇圣,刘晓东.乳腺癌首发肺转移预后多因素分析,肿瘤,2012.

邱梅清、佟仲生、贾勇圣、刘晓东、陈悦.线粒体融合素基因-2过表达对小白菊内酯治疗乳腺癌敏感性的影响,中国肿瘤生物治疗杂志,2012.

路灿,佟仲生,贾勇圣.肿瘤铁代谢研究进展,生理科学进展,2012

刘婷婷,佟仲生,史业辉,郝春芳.选择性COX-2抑制剂对人乳腺癌细胞MCF-7的抑制作用及分子机制研究.中国肿瘤临床,2011,38(5)

沈春燕,穆海玉,王忱,多健,佟仲生. APE1、VEGF在非小细胞肺癌组织中的表达及其与预后的关系.天津医科大学学报,2011,17(2)

沈春燕,穆海玉,佟仲生.葡萄糖转运蛋白1在乳腺癌组织中的表达及与其预后的关系.实用癌症杂志,2011,26(6)

苗培田,佟仲生,郝春芳,张萌.不同亚型转移性乳腺癌转移特点及预后分析.中国肿瘤临床,2011,38(4)

李军楠,刘晓东,佟仲生. T1micN0M0、T1aN0M0和T1bN0M0乳腺癌376例临床特征和预后分析.肿瘤,2011,31(11)

刘晓东,佟仲生,李淑芬,史业辉,汪旭,郝春芳.局部晚期乳腺癌1081例临床病理特征及预后分析,肿瘤,2011,31 (10)

相关链接

天津市肿瘤医院

参考资料